With new methods of regenerative medicine into a
healthier world: The vision of the founders drives the
scientists and biotech experts at ISAR Bioscience
Strong team, great goals
With new methods of regenerative medicine into a healthier world: The vision of the founders drives the scientists and biotech experts at ISAR Bioscience
The history of ISAR Bioscience begins with plans of Hans Schöler at the Max Planck Institute for Molecular Biomedicine in Münster to establish a translational research institute. The aim was to make the results of basic research quickly available for medical use. Specifically, Hans Schöler’s team was interested in new technologies in stem cell research, in particular the so-called iPS cells (= induced pluripotent stem cells). These are stem cells that can be produced from the body’s normal cells such as fibroblasts, and offer researchers an ethically unproblematic alternative to embryonic stem cells. With the help of iPS cells it is possible to generate intact as well as diseased human stem cells. These can then be specifically differentiated into other cells, such as nerve cells or heart cells. They can be used as models for research into the development of diseases, but also for possible new therapies.
The core of the concept is the close cooperation between public research institutions and smaller as well as established companies from biotechnology and pharmaceutical research. ISAR Bioscience sees itself as a bridge-builder between these institutions and creates a direct link between basic research and new therapies and products – in other words, “translation”.
The Free State of Bavaria took up the concept. To start realizing it, private donors established the non-profit Foundation for Stem Cell Research and Applied Regenerative Medicine. The foundation is the sole shareholder of ISAR Bioscience GmbH, which has been in existence since 2018 and is initially funded by the Bavarian Ministry of Economics with 20 million euros.
In the same year, laboratory facilities were set up in Planegg, in the southwest of Munich - in the direct vicinity of numerous research institutions and biotech companies. The Lead Discovery Center of the Max Planck Society, which has its Munich branch in the same building, was of great help in this process. The first research projects in the field of stem cell research and neurodegenerative diseases started as early as 2018. Since then, ISAR Bioscience has been growing both in its research spectrum and in terms of personnel. The declared goal is to become a center of translational biomedicine in the Munich area.
Who we are
ISAR Bioscience GmbH is a Bavarian research company with a worldwide network. We develop regenerative therapies against dementia, heart failure and immune diseases using iPS cells and differentiated human cells derived from them. We use them to test new therapeutic principles and drug candidates.
Our scientists come from the fields of medicine, biology and chemistry, from universities and non-university research institutions, from biotech and pharmaceutical companies.
We work in modern laboratories in Planegg near Munich – at the heart of the biotechnology scene. We do research on our own projects and on issues that we investigate together with partners from our worldwide network. Together, we seek to identify innovative projects, develop them further in collaboration with teams of inventors from public research institutions and industry, and help them become reality.
ISAR Bioscience is led by a team of scientists and biotech entrepreneurs who came with their rich experience in research and development, medicine and business development. We develop and manage our projects and are happy to serve as contacts for current and future partners from research and industry.
Prof. Martin Lohse, MD DSc h.c. Chairman
Prof. Martin Ungerer, MD Chief Scientific Officer, Medicine
Dr. Christiane Schiegerl Head Administration
Dr. Franz Bergmann Project Coordination BASE-Lipid and Head Finance
Dr. Karsten Bräuker Head Law
Dr. Miriam Christlmeier Director of the Neurodegeneration Program
Dr. Christopher Breunig Director of the „Genome Engineering“ Program
Dr. Tim Ammon Director of the „Immunology“ Program
Dr. Martha E. Sommer Director of the „Signalling“ Platform
Dr. Lilia Espada Co-Leader of the „Stem Cell” Platform
Dr. Felix Schuster Co-Leader of the „Stem Cell” Platform
Foundation for stem cell research and applied regenerative medicine
Excellent research and science are the basis for new approaches in medicine and new therapies and at the same time for social progress and prosperity. They cost money and, therefore, require special funding.
In order to further develop the potential of regenerative medicine in general and induced pluripotent stem cells in particular for the benefit of patients, the non-profit Foundation for Stem Cell Research and Applied Regenerative Medicine (StemCellRegMed Foundation) was established in 2017.
Mission of the foundation
The foundation aims to promote applied research and development activities in medicine, especially in regenerative medicine. In this context, the foundation established ISAR Bioscience GmbH. In order to support the application-oriented research of the young company, the foundation also relies on donations, gifts, bequests and other contributions. The money is intended to go towards the foundation’s basic assets or to support the foundation’s funding programs.
Become a co-founder!
You want to make a difference, for example help to fight a specific disease? Do you feel a strong sense of responsibility towards your fellow human beings? Are you considering supporting a selected research institution with your donation or an endowment?
We are happy if you want to support applied medical research as a benefactor or donor. With your donation to our foundation, you support important medical innovations. Your commitment can help to ensure that new and known diseases may be treated better in the future. With your donation you support our work - in a specific manner according to your wishes.
Prof. Dr. Horst Domdey
Phone: +49 (0) 89 / 89 96 79-0
The Supervisory Board monitors the legality, expediency and economic efficiency of the management of ISAR Bioscience. This supervisory body brings together four members from the fields of politics and technology transfer. Dr. Wolter is the Chairman, and Dr. Erselius is his deputy.
Manfred Wolter PhD Chairman; Head of Department Bavarian Ministry of Economic Affairs
Jörn Erselius PhD Deputy Chairman; Managing Director Max Planck Innovation GmbH
Christian Stein PhD Managing Director Ascenion GmbH
Hermann Nafziger Mayor of Planegg
Scientific Advisory Board
For the selection as well as the further development of our research areas and projects, we use not only internal but also external expertise. The scientific advisory board, which combines proven scientific expertise with the perspectives of the pharmaceutical industry and investors, serves this purpose. The members of the scientific advisory board reflect the spectrum of the work of ISAR Bioscience.
Prof. Andreas Busch PhD CIO Cyclerion; former member of the Board of Management of Bayer Health Care
Prof. Thomas Eschenhagen MD Director of the Institute of Pharmacology, University of Hamburg; Chairman of the Board DZHK
Prof. Magdalena Götz PhD Director of the Institute of Stem Cell Research, Helmholtz Center Munich
Prof. Martine Smit PhD Professor of medicinal chemistry, Free University of Amsterdam
ISAR Bioscience cooperates with proven experts in certain scientific and indication areas. They accompany and advise the young research enterprise.
Prof. Dr. Dominik Paquet Professor of Neurobiology, Institute for Stroke and Dementia Research, University of Munich